ATTN LogoMenu

IM Cannabis Corp Shifts Focus to Medical Markets

By ATTN Desk · Editorial oversight: Sean Han

NASDAQ
IMCC

IM Cannabis Corp (IMCC) Overview

IM Cannabis Corp (NASDAQ: IMCC; CSE: IMCC) is an international medical-grade cannabis company headquartered in Israel. Founded over a decade ago, the company develops, imports, and distributes proprietary cannabis strains to medical patients in Israel and Germany. The company ceased its adult-use operations in Canada as of 2025. As of May 28, 2025, IMC shares traded at USD 2.6994, representing a 44.35% increase from the previous close, on a volume of 318,859 shares.

Corporate Structure

  • Geographic Footprint

    • Israel: Operates through a commercial relationship with Focus Medical Herbs Ltd. for import, distribution, and retail through pharmacies and online platforms.
    • Germany: Conducts operations via Adjupharm GmbH, including EU-GMP packing and GDP logistics, primarily distributing to pharmacies.
    • Discontinued Canadian operations as of 2025 to reallocate resources to higher-value markets.

  • Workforce

    • Approximately 201–500 employees (LinkedIn estimate).
    • Employees engage in various roles, including strategic management, quality assurance, research and development (R&D), marketing, and regulatory compliance.

  • Leadership & Governance

    • CEO: Oren Shuster
    • Director, Investor & Public Relations: Anna Taranko
    • Annual General and Special Meeting of Shareholders held in May 2025.

Recent Developments and News

  • 2025-05-28 Stock Performance

    • Closing price: USD 2.6994 (+44.35%).
    • Volume: 318,859 compared to an average daily volume of 11,125 shares.

  • Market Exits and Refocus

    • In Q1 2025, IMCC exited its Canadian adult-use operations to concentrate resources on its medical operations in Israel and Germany.
    • This pivot aims to support sustainable growth in the two largest medical cannabis markets.

  • Corporate Actions

    • Upcoming earnings window: August 12, 2025, to August 18, 2025, according to Yahoo Finance.
    • No dividend declared; trailing EPS (TTM) was -1.38 USD.

Financial and Strategic Analysis

MetricValue
Market Capitalization (intraday)USD 8.37M
Enterprise ValueUSD 16.31M
Revenue (TTM)USD 54.47M
Net Income (TTM)-USD 4.69M
Profit Margin-8.60%
Price/Sales (TTM)0.15×
Price/Book (MRQ)1.49×
Total Cash (MRQ)USD 1.39M
Total Debt/Equity (MRQ)497.26%
Levered Free Cash Flow (TTM)-USD 4.91M

  • Liquidity & Leverage

    • Cash reserves of USD 1.39M against a high debt-to-equity ratio.
    • Negative free cash flow reflects ongoing investments in EU-GMP and distribution capacity.

  • Profitability

    • The company reported a net loss in the trailing twelve months, with strategic initiatives in place aimed at improving margins.
    • A Price/Sales metric below 0.2× indicates the current market valuation accounts for its unprofitability.

  • Strategic Positioning

    • The company maintains vertical integration across cultivation, packaging, and distribution in regulated markets.
    • Data-driven patient insights in Israel are utilized to enhance product offerings and increase market share.
    • EU-GMP certification and its logistics facility in Germany support B2B services to pharmacies.

Market Position and Industry Context

  • Regulatory Environment

    • Operates under strict Ministry of Health approvals in Israel and EU-GMP standards in Germany.
    • Medical cannabis markets in Israel and Germany are among the largest globally and are experiencing significant growth.

  • Competitive Landscape

    • IMCC is one of the few companies with fully integrated operations that span cultivation, processing, retail, and logistics in both Israel and Europe.
    • Main competitors include local EU-licensed producers and global operators, with differentiation achieved through proprietary strains and data analytics.

  • Growth Drivers

    • Increasing adoption of medical cannabis therapies for conditions such as chronic pain, oncology, and neurological disorders.
    • Potential expansion into emerging EU markets (e.g., Portugal, Greece) through existing distribution partnerships.

TL;DR

On May 28, 2025, IMC shares closed at USD 2.6994, up 44.35% on 318,859 shares traded. The company completed its exit from Canadian adult-use operations in Q1 2025 and is reallocating capital and resources to medical markets in Israel and Germany. Key financials for the trailing twelve months include USD 54.47M in revenue, -USD 4.69M in net income, and a 497% debt-to-equity ratio. The next earnings announcement is scheduled between August 12 and August 18, 2025. The firm’s strategy focuses on data-driven product development, EU-GMP certification, and a vertically integrated supply chain.

Latest Stories

Loading articles...